Biocon - Company Intelligence Profile
Industry: Biotechnology Research | Founded: 2004 | HQ: Bangalore, India
Biocon: Enhancing Global Healthcare
Datakart tracks firmographic, hiring, traffic, technology, funding, review, and leadership signals for Biocon to help teams evaluate the account with useful business context.
Company Snapshot
Biocon: Enhancing Global Healthcare
Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high.
The early anticipation of the increasing dominance of biologics in global development pipelines helped us to be ahead of the curve in crafting a differentiated product portfolio based on fermentation and recombinant technologies, which straddles fermentation-derived small molecules and biologics, both novel as well as biosimilars.
The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppresants and other specialty products has made us a leading global supplier of these products.
We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders.
Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Our insulin products have made a difference to the lives of millions of people with diabetes across the globe. We now aim to provide our insulin products to ‘one in five’ people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years.
We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the USFDA; Ogivri™, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the US. In addition to Trastuzumab, several of our biosimilar assets are on track for anticipated regulatory approvals in developed markets.
We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin.
Through our subsidiary, Syngene, we offer a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) to the global life sciences sector.
Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through ‘blockbuster’ drugs with the potential to benefit a billion patients.
Founded
Employee count
Monthly website visits
Open roles
Company Snapshot Details
Business signals that help qualify Biocon
This profile combines firmographic, traffic, hiring, employee, review, compensation, technology, funding, leadership, and product availability signals so visitors can answer practical business questions without hunting across multiple data sources.
Last refreshed 2026-04-30 | 50K search volume | Domain biocon.com
Biocon identity, aliases, ownership, and taxonomy
This section makes the entity easier to verify: canonical domains, alternate names, descriptions, ownership flags, parent or acquirer context, industry codes, and source-level social reach are grouped together.
Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high. The early anticipation of the increasing dominance of biologics in global development pipelines helped us to be ahead of the curve in crafting a differentiated product portfolio based on fermentation and recombinant technologies, which straddles fermentation-derived small molecules and biologics, both novel as well as biosimilars. The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppresants and other specialty products has made us a leading global supplier of these products. We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders. Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Our insulin products have made a difference to the lives of millions of people with diabetes across the globe. We now aim to provide our insulin products to ‘one in five’ people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years. We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the USFDA; Ogivri™, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the US. In addition to Trastuzumab, several of our biosimilar assets are on track for anticipated regulatory approvals in developed markets. We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin. Through our subsidiary, Syngene, we offer a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) to the global life sciences sector. Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through ‘blockbuster’ drugs with the potential to benefit a billion patients.
Biocon is an innovation led fully integrated biopharmaceutical company that develops affordable biosimilars, generic formulations & complex APIs.
Biocon is an innovation led fully integrated biopharmaceutical company that develop affordable biosimilars, generic formulations & complex APIs
LinkedIn followers
1.1M
Latest linkedin followers value available from the source dataset.
Owler followers
505
Latest owler followers value available from the source dataset.
Technologies detected
148
Latest technologies detected value available from the source dataset.
Operating status
Active
Merged
Company type
Public Company
type
Ownership status
Public
Ownership Status
Public company
Yes
Is Public
Parent company
Biosimilars Division, Viatris Inc.
2022-02-01
Acquired by
Nephros
2019-01-02
Company alias
biocon
Company Name Alias
Company alias
biocon limited
Company Name Alias
Company alias
biocon ltd
Company Name Alias
Website alias
https://www.biocon.com
Website Alias
Website alias
https://www.biocon.com/
Website Alias
Canonical website
https://www.biocon.com
website
Website domain
biocon.com
Website Domain
Unique website
Yes
Unique Website
Unique domain
Yes
Unique Domain
Expired domain
No
Expired Domain
LinkedIn shorthand
biocon
Canonical LinkedIn Shorthand Name
Source ID
162713
Source ID
UUID
78S4PXAXK9PC29J4TACQNT2VE9
uuid
Industry
Biotechnology Research
industry
Categories and keywords
['biopharmaceutical', 'generic formulations', 'innovation', 'complex apis', 'affordable biosimilars', 'health', 'biotech', 'drug-development', 'pharma', 'biopharma', 'biotechnology', 'health care', 'medical']
Categories And Keywords
LinkedIn followers
1.1M
Followers Count LinkedIn
Owler followers
505
Followers Count Owler
Primary location
Hosur Road, Electronics City; Bangalore, Karnataka 560100, IN
Office location
20th KM, Hosur Road; Bengaluru, Karnataka, India
Office location
20th KM, Hosur Road, Electronic City; Bangalore, 560100, India
Office location
Bangalore, Karnataka, India
Biocon revenue, funding, IPO, and acquisition history
Financial signals are grouped as an analyst-style view: revenue sources, income statement rows, funding rounds, acquisition activity, IPO fields, stock listing context, and ownership structure.
Source 5
$1.9B
Annual revenue
IPO date
2004-04-07
IPO Date
Operating status
Active
Merged
Company type
Public Company
type
Ownership status
Public
Ownership Status
Public company
Yes
Is Public
Parent company
Biosimilars Division, Viatris Inc.
2022-02-01
Acquired by
Nephros
2019-01-02
Q3, 2026
Q3
Primary value
Revenue: INR 41.2B
Additional metrics
Gross profit: INR 29.5B; EBITDA: INR 9.5B; EBIT: INR 1.4B; Net income: INR -518M; Operating expense: INR 20B; Gross margin: 71.6%; EBITDA margin: 23.1%
Q2, 2026
Q2
Primary value
Revenue: INR 42.6B
Additional metrics
Gross profit: INR 26.3B; EBITDA: INR 8.4B; EBIT: INR 3.4B; Net income: INR 1.3B; Operating expense: INR 18B; Gross margin: 61.8%; EBITDA margin: 19.6%
Q1, 2026
Q1
Primary value
Revenue: INR 39.1B
Additional metrics
Gross profit: INR 26.5B; EBITDA: INR 8.3B; EBIT: INR 3.7B; Net income: INR 892M; Operating expense: INR 18.2B; Gross margin: 67.8%; EBITDA margin: 21.2%
FY, 2025
Fiscal Year
Primary value
Revenue: INR 150.5B
Additional metrics
Gross profit: INR 100.6B; EBITDA: INR 42.9B; EBIT: INR 27B; Net income: INR 14.3B; Operating expense: INR 68.3B; Gross margin: 66.9%; EBITDA margin: 28.5%
Q3, 2025
Q3
Primary value
Revenue: INR 37.7B
Additional metrics
Gross profit: INR 25B; EBITDA: INR 7.9B; EBIT: INR 3.8B; Net income: INR 811M; Operating expense: INR 17.1B; Gross margin: 66.2%; EBITDA margin: 20.8%
Q2, 2025
Q2
Primary value
Revenue: INR 35.4B
Additional metrics
Gross profit: INR 12.4B; EBITDA: INR 6.9B; EBIT: INR 3B; Net income: INR 271M; Operating expense: INR 16.1B; Gross margin: 35.0%; EBITDA margin: 19.5%
Q1, 2025
Q1
Primary value
Revenue: INR 33.8B
Additional metrics
Gross profit: INR 34.2B; EBITDA: INR 17.5B; EBIT: INR 13.8B; Net income: INR 8.6B; Operating expense: INR 16.6B; Gross margin: 1.0%; EBITDA margin: 52.0%
FY, 2024
Fiscal Year
Primary value
Revenue: INR 142B
Additional metrics
Gross profit: INR 101.9B; EBITDA: INR 38B; EBIT: INR 22.2B; Net income: INR 13B; Operating expense: INR 64.1B; Gross margin: 71.7%; EBITDA margin: 26.8%
Q3, 2024
Q3
Primary value
Revenue: INR 35.5B
Additional metrics
Gross profit: INR 32.9B; EBITDA: INR 14.7B; EBIT: INR 10.7B; Net income: INR 7.5B; Operating expense: INR 18B; Gross margin: 92.6%; EBITDA margin: 41.4%
Q2, 2024
Q2
Primary value
Revenue: INR 34.6B
Additional metrics
Gross profit: INR 24.9B; EBITDA: INR 8.8B; EBIT: INR 4.6B; Net income: INR 1.7B; Operating expense: INR 15.9B; Gross margin: 71.9%; EBITDA margin: 25.3%
Q1, 2024
Q1
Primary value
Revenue: INR 34.2B
Additional metrics
Gross profit: INR 23.1B; EBITDA: INR 7.7B; EBIT: INR 4.2B; Net income: INR 1.5B; Operating expense: INR 15B; Gross margin: 67.5%; EBITDA margin: 22.6%
FY, 2023
Fiscal Year
Primary value
Revenue: INR 109.3B
Additional metrics
Gross profit: INR 78.5B; EBITDA: INR 27.3B; EBIT: INR 13.3B; Net income: INR 6.4B; Operating expense: INR 49.5B; Gross margin: 71.8%; EBITDA margin: 25.0%
| Period | Primary value | Additional metrics |
|---|---|---|
Q3, 2026 Q3 | Revenue: INR 41.2B | Gross profit: INR 29.5B; EBITDA: INR 9.5B; EBIT: INR 1.4B; Net income: INR -518M; Operating expense: INR 20B; Gross margin: 71.6%; EBITDA margin: 23.1% |
Q2, 2026 Q2 | Revenue: INR 42.6B | Gross profit: INR 26.3B; EBITDA: INR 8.4B; EBIT: INR 3.4B; Net income: INR 1.3B; Operating expense: INR 18B; Gross margin: 61.8%; EBITDA margin: 19.6% |
Q1, 2026 Q1 | Revenue: INR 39.1B | Gross profit: INR 26.5B; EBITDA: INR 8.3B; EBIT: INR 3.7B; Net income: INR 892M; Operating expense: INR 18.2B; Gross margin: 67.8%; EBITDA margin: 21.2% |
FY, 2025 Fiscal Year | Revenue: INR 150.5B | Gross profit: INR 100.6B; EBITDA: INR 42.9B; EBIT: INR 27B; Net income: INR 14.3B; Operating expense: INR 68.3B; Gross margin: 66.9%; EBITDA margin: 28.5% |
Q3, 2025 Q3 | Revenue: INR 37.7B | Gross profit: INR 25B; EBITDA: INR 7.9B; EBIT: INR 3.8B; Net income: INR 811M; Operating expense: INR 17.1B; Gross margin: 66.2%; EBITDA margin: 20.8% |
Q2, 2025 Q2 | Revenue: INR 35.4B | Gross profit: INR 12.4B; EBITDA: INR 6.9B; EBIT: INR 3B; Net income: INR 271M; Operating expense: INR 16.1B; Gross margin: 35.0%; EBITDA margin: 19.5% |
Q1, 2025 Q1 | Revenue: INR 33.8B | Gross profit: INR 34.2B; EBITDA: INR 17.5B; EBIT: INR 13.8B; Net income: INR 8.6B; Operating expense: INR 16.6B; Gross margin: 1.0%; EBITDA margin: 52.0% |
FY, 2024 Fiscal Year | Revenue: INR 142B | Gross profit: INR 101.9B; EBITDA: INR 38B; EBIT: INR 22.2B; Net income: INR 13B; Operating expense: INR 64.1B; Gross margin: 71.7%; EBITDA margin: 26.8% |
Q3, 2024 Q3 | Revenue: INR 35.5B | Gross profit: INR 32.9B; EBITDA: INR 14.7B; EBIT: INR 10.7B; Net income: INR 7.5B; Operating expense: INR 18B; Gross margin: 92.6%; EBITDA margin: 41.4% |
Q2, 2024 Q2 | Revenue: INR 34.6B | Gross profit: INR 24.9B; EBITDA: INR 8.8B; EBIT: INR 4.6B; Net income: INR 1.7B; Operating expense: INR 15.9B; Gross margin: 71.9%; EBITDA margin: 25.3% |
Q1, 2024 Q1 | Revenue: INR 34.2B | Gross profit: INR 23.1B; EBITDA: INR 7.7B; EBIT: INR 4.2B; Net income: INR 1.5B; Operating expense: INR 15B; Gross margin: 67.5%; EBITDA margin: 22.6% |
FY, 2023 Fiscal Year | Revenue: INR 109.3B | Gross profit: INR 78.5B; EBITDA: INR 27.3B; EBIT: INR 13.3B; Net income: INR 6.4B; Operating expense: INR 49.5B; Gross margin: 71.8%; EBITDA margin: 25.0% |
Post-IPO Debt
$200.8M
2025-12-01 | Axis Mutual Fund, SBI Mutual Fund
Post-IPO Equity
$519.6M
2025-07-20 | ICICI Prudential Mutual Fund, Government Pension Fund Global, HDFC Standard Life Insurance, BlackRock, Nippon India Mutual Fund, Aditya Birla Sunlife Mutual Fund, Mirae Asset Mutual Fund, SBI General Insurance, Franklin Templeton, SBI Mutual Fund
Post-IPO Equity
$520.5M
2025-06-01
Post-IPO Debt
$70.4M
2025-04-01
Post-IPO Equity
$129.2M
2023-02-22 | Kotak Alternate Asset Managers
Post-IPO Equity
INR 5.5B
2021-01-01 | adQ
Post-IPO Equity
2004-04-01
Post-IPO Equity
J.P. Morgan Asset Management, Mirae Asset Mutual Fund, ICICI Prudential Life Insurance, ICICI Prudential Mutual Fund, HDFC Standard Life Insurance, SBI Mutual Fund, Aditya Birla Sunlife Mutual Fund
Biocon Biologics Limited
$5.5B
2025-12-01 | Acquisition List Source 5
Eywa Pharma Inc's Oral Solid Dosage Manufacturing Facility
$7.7M
2023-09-01 | Acquisition List Source 5
Viatris's Biosimilars Business
$3.3B
2022-02-01 | Acquisition List Source 5
AxiCorp GmbH
Acquisition
2008-02-11 | Acquisition List Source 1
axicorp GmbH
$45.3M
2008-02-01 | Acquisition List Source 5
Biocon Biologics Limited
Acquisition
Acquisition List Source 1
Biocon Biologics do Brasil Ltda.
Acquisition
Acquisition List Source 1
Syngene USA Inc.
Acquisition
Acquisition List Source 1
Biofusion Therapeutics Limited
Acquisition
Acquisition List Source 1
Biocon Biologics UK Limited
Acquisition
Acquisition List Source 1
Syngene International Limited
Acquisition
Acquisition List Source 1
Biocon Biologics Inc.
Acquisition
Acquisition List Source 1
Biocon SA
Acquisition
Acquisition List Source 1
Biocon Pharma UK Limited
Acquisition
Acquisition List Source 1
Biocon Biosphere Limited
Acquisition
Acquisition List Source 1
Biocon Pharma Limited
Acquisition
Acquisition List Source 1
Biocon Pharma Malta I Limited
Acquisition
Acquisition List Source 1
Biocon Sdn Bhd
Acquisition
Acquisition List Source 1
Bicara Therapeutics Inc
Acquisition
Acquisition List Source 1
Biocon Academy
Acquisition
Acquisition List Source 1
Biocon Pharma Malta Limited
Acquisition
Acquisition List Source 1
Biocon Biologics FZ–LLC
Acquisition
Acquisition List Source 1
Biocon Pharma Inc.
Acquisition
Acquisition List Source 1
Biocon Biologics Healthcare Malaysia SDN. BHD
Acquisition
Acquisition List Source 1
Biocon FZ LLC.
Acquisition
Acquisition List Source 1
Biocon Pharma Ireland Limited
Acquisition
Acquisition List Source 1
Web visibility, demand, and topics
Use these signals to understand discoverability, demand quality, search interest, and audience fit.
Monthly visits
83.2K
Latest monthly visits value available from the source dataset.
Global web rank
#368,878
Lower rank values indicate stronger web visibility in the source dataset.
Bounce rate
39.0%
Latest bounce rate value available from the source dataset.
Pages per visit
3.8
Latest pages per visit value available from the source dataset.
Average visit duration
1m 44s
Latest average visit duration value available from the source dataset.
Estimated monthly page views
316.3K
Derived estimate calculated as monthly visits multiplied by pages per visit.
biocon
Associated search topic
kiran mazumdar-shaw
Associated search topic
biocon limited
Associated search topic
biocom india phama
Associated search topic
biospace
Associated search topic
LinkedIn followers
1.1M
Followers Count LinkedIn
Owler followers
505
Followers Count Owler
Employees, hiring, attrition, and compensation
This section groups org scale, hiring motion, employee movement, department mix, and salary benchmarks so teams can qualify operating momentum and budget signals.
Employees
11.7K
Latest employees value available from the source dataset.
Inferred employees
4.9K
Latest inferred employees value available from the source dataset.
Open roles
2
Latest open roles value available from the source dataset.
Departures
0
Latest departures value available from the source dataset.
Employee attrition rate
0.0%
Latest employee attrition rate value available from the source dataset.
Hiring intensity
0.2 roles / 1K employees
Derived signal showing open roles normalized by employee count.
Video Editor/Graphic Designer
Open role
4406939637
External Media Lead– Global Communications
Open role
4402359854
Showing 8 of 10 available records.
Showing 8 of 10 available records.
Scientist
MYR $33.6K
Monthly | Updated 2023-12-25
Manufacturing Executive
INR $514.7K
Annual | Updated 2024-06-13
Management Trainee
INR $152.8K
Monthly | Updated 2024-06-25
Research Assistant
INR $403.9K
Monthly | Updated 2024-09-18
Associate Manager
MYR $156K
Annual | Updated 2024-06-24
Sales Executive
INR $488.8K
Annual | Updated 2023-02-02
Quality Assurance Analyst
INR $323.2K
Monthly | Updated 2024-08-09
Regulatory Affairs Specialist
INR $682.6K
Monthly | Updated 2024-02-20
Showing 8 of 10 available records.
Technician
Cash Bonus $2.7K; Profit Sharing $3.1K
Monthly | Updated 2024-07-09
Deputy Manager
Cash Bonus $50K
Annual | Updated 2024-07-01
Finance Executive
Cash Bonus $13.6K
Annual | Updated 2022-12-02
Research Scientist
Cash Bonus $7.9K
Annual | Updated 2024-04-25
Senior Executive Quality Assurance
Cash Bonus $11K
Annual | Updated 2024-08-09
QA Analyst
Cash Bonus $41.3K
Annual | Updated 2024-08-09
Quality Control Executive
Cash Bonus $9.9K
Monthly | Updated 2024-07-25
Regional Business Manager
Commission Sharing $312.9K
Annual | Updated 2023-04-24
Showing 8 of 10 available records.
Research Assistant
INR $403.9K
Monthly | Updated 2024-09-18
Senior Research Associate
INR $349.8K
Monthly | Updated 2024-09-18
Quality Control Microbiologist
INR $360K
Monthly | Updated 2024-09-03
Junior Associate
MYR $34K
Monthly | Updated 2024-08-26
Production Engineer
MYR $39K
Monthly | Updated 2024-08-25
Executive Production
INR $494.4K
Annual | Updated 2024-08-23
Production Supervisor
INR $466.5K
Monthly | Updated 2024-08-23
Associate Scientist
INR $820K
Annual | Updated 2024-08-20
Showing 8 of 10 available records.
Product readiness, customer proof, and employee sentiment
Product availability, public reviews, and employee sentiment help visitors understand whether the company is mature, documented, reviewable, and operationally healthy.
Employee reviews
11
Latest employee reviews value available from the source dataset.
Employee rating
3.8
Latest review score available from the source dataset.
Is pricing information available?
No. The source snapshot does not list pricing information for this company.
Source availability signal
Is a free trial listed?
No. The source snapshot does not list a free trial for this company.
Source availability signal
Can buyers request a demo?
No. The source snapshot does not list a demo motion for this company.
Source availability signal
Is the product downloadable?
No. The source snapshot does not list downloadable software for this company.
Source availability signal
Are mobile apps listed?
No. The source snapshot does not list mobile apps for this company.
Source availability signal
Is public documentation listed?
No. The source snapshot does not list public documentation for this company.
Source availability signal
Are online reviews listed?
No. The source snapshot does not list online reviews for this company.
Source availability signal
Technology, leadership, competitors, funding, and corporate activity
These data points help sales, partnerships, analysts, and researchers understand how the company operates, who surrounds it, and where it may be moving next.
Elog
Verified technology
Last verified 2026-05-04 | First seen 2025-08-17
Agilent
Verified technology
Last verified 2026-05-04 | First seen 2024-05-20
Foresee
Verified technology
Last verified 2026-05-04 | First seen 2025-08-17
Ladder Logic
Verified technology
Last verified 2026-05-04 | First seen 2025-08-17
Microsoft
Verified technology
Last verified 2026-05-04 | First seen 2024-04-04
Iam
Verified technology
Last verified 2026-05-04 | First seen 2024-05-20
Trackwise
Verified technology
Last verified 2026-05-04 | First seen 2025-08-17
Honeywell
Verified technology
Last verified 2026-05-04 | First seen 2025-08-17
Showing 8 of 24 available records.
Showing 8 of 12 available records.
Santosh Mathias
Associate Director
Babu Gowda
Executive
Karthick Selavaraj
Executive
Somashekhar Dhannur
Project Engineer
Yogish Rudra
Group Head Indirect Taxation - Biocon Group
Pooja Kanamadi
Executive
Kathleen Blanchard
Senior Vice President, Global General Counsel
Jaya Bharath P
Senior Director - Human Resources
Showing 8 of 12 available records.
Sahana Kulkarni
Executive
Mar 2026
Naveen Narayanan
Chief Human Resources Officer
Apr 2026
MBBS DR. GURSHARAN SINGH
General Manager & Head, Medical Sciences- Clinical Development and Medical Affairs, Biocon Limited
Apr 2026
Kathleen Blanchard
Senior Vice President, Global General Counsel
Apr 2026
Sumit Katyal
AVP - HR | Global Head Total Rewards
Apr 2026
Mandar Ghatnekar
Chief Technology Officer
Apr 2026
Meghana Sripada
Executive
Feb 2026
Adavivarapu Divakar
Executive
Jan 2026
Subbarao Ch L N V
Senior Director (MSAT)
Jan 2026
Sudharsan B L
HR Business Partner
Feb 2026
KESAVAN M
Executive
Dec 2025
Ankur Chavan
Senior Director (DGM) - IT
Dec 2025
Maninder Kapoor Puri
Chief Human Resources Officer
May 2026
Hari Prasadh S
Executive
Apr 2026
Vishal Pawar
Executive
Jan 2026
Muguntan Govindaraju
Associate Director Quality Assurance
Mar 2026
Primary location
Hosur Road, Electronics City; Bangalore, Karnataka 560100, IN
Office location
20th KM, Hosur Road; Bengaluru, Karnataka, India
Office location
20th KM, Hosur Road, Electronic City; Bangalore, 560100, India
Office location
Bangalore, Karnataka, India
At Biocon, we align our operations closely with the United Nations Sustainable Development Goals, embedding s…
58 reactions; 1 comments
2026-04-29 | At Biocon, we align our operations closely with the United Nations Sustainable Development Goals, embedding sustainable practices into everyday action. Through our Sustainable Corporate Commute initiative, Biocon is wo…
Bengaluru just got a new soul — and you can see it the moment you land. At the Arrival Forecourt of Terminal…
232 reactions; 3 comments
2026-04-27 | Bengaluru just got a new soul — and you can see it the moment you land. At the Arrival Forecourt of Terminal 2, Kempegowda International Airport Bengaluru, “Bengaluru’s Soul,” a striking new cultural landmark by critic…
At CNBC International Converge Live 2026 in Singapore, Shreehas Tambe, CEO & MD, Biocon Limited, spoke about…
90 reactions; 3 comments
2026-04-25 | At CNBC International Converge Live 2026 in Singapore, Shreehas Tambe, CEO & MD, Biocon Limited, spoke about the evolving role of AI in healthcare and what it will take to deliver impact at scale. Joining Alex Zhavoron…
We are pleased to share that with a new approval from Health Canada, Biocon is expanding its treatment option…
92 reactions; 1 comments
2026-04-21 | We are pleased to share that with a new approval from Health Canada, Biocon is expanding its treatment options in Canada for osteoporosis and bone metastasis, a common complication of advanced cancer. This reflects our…
Japan has long been a strategic market for Biocon, where science, scale and partnerships come together to sup…
118 reactions; 3 comments
2026-04-20 | Japan has long been a strategic market for Biocon, where science, scale and partnerships come together to support the healthcare system. At CPHI Japan 2026, we look forward to engaging with stakeholders across the ecos…
Sustainability is increasingly shaping how businesses build, scale and stay relevant. At Biocon, we embed re…
34 reactions
2026-04-18 | Sustainability is increasingly shaping how businesses build, scale and stay relevant. At Biocon, we embed responsible practices into every layer of our operations, guided by science and focused on long-term impact. Ra…
Industry
Biotechnology Research
industry
Categories and keywords
['biopharmaceutical', 'generic formulations', 'innovation', 'complex apis', 'affordable biosimilars', 'health', 'biotech', 'drug-development', 'pharma', 'biopharma', 'biotechnology', 'health care', 'medical']
Categories And Keywords
Biocon FAQs
Company profile
Want verified contact data for Biocon?
Datakart.ai gives you verified email addresses, direct dials, and buying intent signals for key decision-makers at Biocon and 1,700+ other companies.